Clinical Presentation and Outcome of Critically Ill Patients with Inflammatory Bowel Disease

Abstract

<b><i>Introduction:</i></b> Admission to the intensive care unit severely affects inflammatory bowel disease (IBD) patients. This study aimed to determine factors associated with mortality in IBD patients admitted to the intensive care unit. <b><i>Methods:</i></b> A retrospective cohort study was performed, analyzing data of all IBD patients admitted to the Department of Intensive Care Medicine at the University Medical Center Hamburg-Eppendorf between 2013 and 2022. Bivariate comparisons and multivariate regression analyses were performed to identify factors associated with mortality. <b><i>Results:</i></b> Overall, 439 IBD patients were admitted to the intensive care unit, representing 0.56% of total admissions. In 98 of these patients, IBD-associated complications were accountable for admission (22.3%). In detail, 39 (40.8%) patients were admitted after IBD-related surgery, 36 (35.7%) due to infections, and 23 (23.5%) due to medical conditions such as bleeding or electrolyte derangement. A total of 16 (16.3%) of these patients died within 90 days after admission. Parameters associated with increased mortality were age (<i>p</i> &lt; 0.001), later age at diagnosis (<i>p</i> 0.026), catecholamine therapy (<i>p</i> 0.003), mechanical ventilation (<i>p</i> &lt; 0.001), renal replacement therapy (<i>p</i> &lt; 0.001), and parenteral nutrition (<i>p</i> 0.002). Prior treatment with anti-TNF therapy was associated with a higher chance of survival (<i>p</i> 0.018). There was no association between prior immunosuppressant therapy and admission because of infections (<i>p</i> 0.294). <b><i>Conclusions:</i></b> 16.3% of IBD patients admitted to the intensive care unit died within 90 days after admission. Prior treatment with anti-TNF therapy was associated with a higher chance of survival.